ABCG2 and cancer: Our results revealed that, although ensartinib could block P-gp-mediated drug efflux at higher concentrations, it could not resensitize P-gp- or ABCG2-overexpressing cancer cells to cytotoxic drugs at non-toxic low concentrations.